A.A. ALEKSEEVA¹, S.V. KRISHTOPENKO², D.I. ABDULGANIEVA³

 ¹Family Doctor’s Clinic, Nizhny Novgorod

²Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko, Nizhny Novgorod

³Kazan State Medical University, Kazan

 Contact details:

Alekseeva A.А. — general practitioner

Address: 4 Kostina St., Nizhny Novgorod, Russian Federation, 603000, tel.: +7-920-004-56-15, e-mail: anastasyalekseeva1998@mail.ru

 The purpose — to study the treatment of ulcerative colitis (UC) as monotherapy with budesonide MMX and combined therapy with budesonide MMX with mesalazine by comparing the dose-response relationship.

Materials and methods. The study included 41 patients with moderately active UC. The patients were divided into 2 groups: the first group (20 patients) was prescribed monotherapy with budesonide MMX at a standard dose of 9 mg per day; the second group (21 patients) received budesonide MMX at a dose of 9 mg with mesalazine at a dose of 3 g orally. The duration of treatment in both groups was 8 weeks. The UC severity at the beginning and after treatment was assessed using the full Mayo activity index. The construction of the dose-effect relationship (efficiency function) was carried out using the original technology developed by S.V. Krishtopenko et al. calculating the dose of budesonide in mg per 1 kg of body weight.

Results. The difference in achieving clinical and endoscopic remission between the two groups of patients at the end of therapy was 17.1%, which did not reach statistical significance (p > 0.05). The construction and analysis of efficiency functions in both groups made it possible to establish that the combination of budesonide with mesalazine was 19.1% (p < 0.05) more effective only in patients weighing more than 82 kg.

Conclusion. The analysis of dose-effect dependencies revealed the greater effectiveness of combination therapy of budesonide MMX with mesalazine, which significantly increased in patients weighing more than 82 kg.

Key words: ulcerative colitis, topical corticosteroids, 5-ASA, dose-effect.

REFERENCES

1. Bonovas S., Nikolopoulos G.K., Lytras T., Fiorino G., Peyrin-Biroulet L., Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: systematic review and network meta-analysis. Br. J. Clin. Pharmacol, 2018, vol. 84 (2), pp. 239–251. DOI: 10.1111/bcp.13456
2. Sandborn W.J., Travis S., Moro L. et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology, 2012, vol. 143 (5), pp. 1218–1226. DOI: 10.1053/j.gastro.2012.08.003
3. Travis S.P.L., Danese S., Kupcinskas L. et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut, 2014, vol. 63 (3), pp. 433–441. DOI: 10.1136/gutjnl-2012-304258
4. D’Haens G.R., Kovács A., Vergauwe P., Nagy F., Molnár T., Bouhnik Y. et al. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J. Crohns. Colitis, 2010, Vol. 4 (2), pp. 153–160. DOI: 10.1016/j.crohns.2009.09.007
5. Rubin D.T., Cohen R.D., Sandborn W.J., Lichtenstein G.R., Axler J., Riddell R.H. et al. Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: a randomised, placebo-controlled trial.. J. Crohns. Colitis, 2017, vol. 11 (7), pp. 785–791. DOI: 10.1093/ecco-jcc/jjx032
6. Danese S., Hart A., Dignass A., Fiorino G., Louis E., Bonovas S. G. et al. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis. United Eur. Gastroenterol. J, 2019, vol. 7, pp. 1171–1182. DOI: 10.1177/2050640619864848
7. Maconi G., Mezzina N., Landi S., Grillo S., Bezzio C., Bosani M. et al. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience. United European Gastroenterol. J, 2019, vol. 7 (9), pp. 1164–1170. DOI: 10.1177/2050640619864257
8. Makarchuk P.A., Britkina O.S. Belousova E.A. Budesonide MMX in the treatment of ulcerative colitis. Real clinical practice. Al’manakh klinicheskoy meditsiny, 2019, vol. 47, no. 6, pp. 505–510 (in Russ.). DOI: 10.18786/2072-0505-2019-47-064
9. Sherlock M.E., MacDonald J.K., Griffiths A.M., Steinhart A.H., Seow C.H. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, 2015, vol. 10. DOI: 10.1002/14651858.CD007698.pub3
10. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med, 1987, vol. 317 (26), pp. 1625–1629. DOI: 10.1056/ NEJM198712243172603
11. D’Haens G., Sandborn W.J., Feagan B.J., Geboes K., Hanauer S.B., Irvine E.J. et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology, 2007, vol. 132 (2), pp. 763–786. DOI: 10.1053/j.gastro.2006.12.038
12. Krishtopenko S.V., Tikhov M.S., Popova E.B. Doza — effect [Dose — effect]. Moscow: Meditsina, 2008. 288 p.
13. Khardle V. Prikladnaya neparametricheskaya regressiya. Per. s angl. [Applied nonparametric regression. Translated from English]. Moscow: Mir, 1993. 352 p.
14. Lakin G.F. Biometriya [Biometrics]. Moscow: Vysshaya shkola, 1990. 350 p.
15. Nguyen N.H., Fumery M., Dulai P.S., Prokop L.J., Sandborn W.J., Murad M.H., Singh S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol. Hepatol, 2018, vol. 3 (11), pp. 742–753. DOI: 10.1016/S2468-1253(18)30231-0